Medline (MDLN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
9 Jun, 2026Quality and recall management
Recent FDA warning letter at the Waukegan facility was anticipated due to self-identified issues; plant was proactively shut down for remediation.
Recalls are voluntary, with 15 this year and 29 last year, out of 190,000 products; response focuses on minimizing customer impact and maintaining supply.
Redundancy in manufacturing and distribution allows for rapid product replacement and fulfillment during recalls.
Significant investments in quality, including $10 million in the Waukegan plant and a global quality team of 2,700+ people.
Financial impact of recalls and plant shutdowns is not material, and guidance remains unchanged.
Financial performance and guidance
First quarter organic growth reached about 10%, with overall growth near 11% unadjusted and 13% adjusted for days.
Acute care channel grew close to 12%, non-acute at 7%, and international at 10%.
Full-year organic sales guidance raised to 8.5%-9.5% due to strong demand and share gains.
Guidance incorporates potential softness in patient volume in the second half, but higher acuity and utilization offset volume declines.
EBITDA guidance for the year is $3.5-$3.6 billion, with stronger performance expected in the second half due to tariff relief and seasonality.
Business drivers and growth strategy
Prime vendor contracts are a key driver, with $2.4 billion sold last year, above the $1 billion annual target.
Outsized wins attributed to delayed price increases, value positioning, and healthcare consolidation.
Medline brand penetration typically doubles in the first year of new contracts, with ongoing incremental gains in subsequent years.
Lab and diagnostics, surgical solutions, and frontline care segments are all contributing to growth, with lab and diagnostics expected to recover in the back half.
Large addressable market remains, with significant share opportunities in acute care, post-acute, surgery centers, and physician offices.
Latest events from Medline
- All board nominees and proposals were approved amid strong growth and strategic investments.MDLN
AGM 202611 Jun 2026 - Strong growth and resilience driven by scale, innovation, and customer-focused execution.MDLN
46th Annual William Blair Growth Stock Conference3 Jun 2026 - Secondary sale of 60 million shares highlights strong growth, high margins, and no proceeds to the company.MDLN
Registration filing20 May 2026 - Q1 2026 sales up 10.7%–11% to $7.4B; margins fell, but full-year sales guidance was raised.MDLN
Q1 202612 May 2026 - Key votes include director elections, executive pay, auditor ratification, and sustainability options.MDLN
Proxy filing23 Apr 2026 - 2025 saw double-digit sales growth, a public listing, and enhanced governance and ESG focus.MDLN
Proxy filing23 Apr 2026 - 2025 saw 11.5% sales growth, record signings, and IPO success, with strong 2026 outlook.MDLN
Q4 202516 Apr 2026 - 2026 outlook targets 8%-9% organic growth, margin expansion, and continued market share gains.MDLN
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - 75 million shares offered by selling stockholders; strong recurring revenue and growth outlook.MDLN
Registration Filing3 Mar 2026